Servier Canada, the Canadian subsidiary of French pharmaceutical company Servier, recently opened its Clinical Development Centre in Laval, in the greater Montréal area. Construction of the facility was announced in September 2013.
“We are very proud to be opening our new centre of excellence in clinical development just over one year after announcing the project,” said Servier Canada’s CEO Frédéric Fasano. “This $17-million investment illustrates the importance of research to our growth model. All in all, we have invested more than $100 million in Canada over the past five years.”
The new centre will take part in Servier’s global clinical research efforts to develop medication to treat cardiovascular and neuropsychiatric diseases as well as certain cancers. The centre will work with internationally renowned partners such as the Montréal Heart Institute, INRS, the Research Centre of the Centre hospitalier de l’Université de Montréal (CRCHUM) and the McGill University Health Centre (MUHC).
Servier’s substantial investment in the facility was made possible by strategic support and $1 million in financial assistance from Investissement Québec.
Servier Canada has also announced the creation of the Dr. Madeleine Tremblay Servier and Groupe Servier Fund for the Development of Medicinal Products at the Université de Montréal Faculty of Pharmacy. The $750,000 fund will be dedicated to educating future talent in the pharmaceutical industry. It is named after Québec-born Dr. Madeleine Tremblay Servier, a graduate of Université de Montréal’s Faculty of Pharmacy who went on to found Servier Canada.
See the September 2013 press release
To read the article published in The Gazette